Tonix Prelim Q3: TONMYA Revenue $14-15M, Cash Jumps to $162.8M
TNXP is trading near its 52-week low of $6.01 (6.8% above the low) on elevated volume (2.4× avg).
Summary
Tonix pre-announced Q3 TONMYA revenue of $14-15 million and about $162.8 million in cash, a big improvement from the going-concern warning in its August 10-Q.
Key Events · Earnings and Guidance · TNXP
-
Preliminary Q3 TONMYA Revenue $14-15M
Estimated net revenue for the quarter ended September 30, 2026 is $14.0-15.0 million, up from $11 million in Q2 2026.
-
Cash Position Estimated at $162.8M
Cash and cash equivalents estimated at approximately $162.8 million as of September 30, 2026, versus the prior 10-Q disclosure that runway only extended into early Q2 2027.
-
Preliminary, Subject to Adjustment
Figures are unaudited management estimates; quarter-end closing procedures and adjustments could materially change the final results.
-
Patent Challenge Backdrop
Comes after Dr. Reddy's filed a Paragraph IV ANDA on October 2 challenging all four patents protecting TONMYA.
Analysis · TNXP · Life Sciences
The key number in Tonix's preliminary third-quarter disclosure is cash: roughly $162.8 million as of September 30, against a prior 10-Q (August 10) that said runway only extended into early Q2 2027 and raised substantial doubt about the company's ability to continue as a going concern. A materially larger cash balance pushes that survival question further out and buys time to defend TONMYA against the Paragraph IV patent challenge filed by Dr. Reddy's on October 2. Revenue also matters: TONMYA net revenue came in at $14.0-15.0 million, up from $11 million in Q2, showing the commercial launch is scaling rather than stalling. These are preliminary, unaudited estimates subject to quarter-end closing adjustments, so the final 10-Q numbers could differ.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 977 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNXP was trading at $6.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $109.8M. The 52-week trading range was $6.01 to $20.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.